Panakes Partners
VC Fund
Milano, Italy
Panakes Partners is a VC fund in Milano focused on Health Care and Medical. Panakès Partners is a Venture Capital firm, based in Milan, which invests in the most ambitious companies and teams, developing revolutionary technologies and products, in the field of life sciences, aiming to improve the lives of people around the world. Panakès, founded in 2015 by Fabrizio Landi, Alessio Beverina and Diana Saraceni, has 250million under management.
- Total investments:
- 42
- Last investment:
- Lead investor:
- 50%
- Fund size:
- $187M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Panakes Partners invests in
Stages Panakes Partners invests in
Countries Panakes Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $4.5M–$79M
- Series B
- $10M–$60M
- Series C
- $18M–$110M
Investment Focus
Industry
- Health Care 18 (43%)
- Medical 13 (31%)
- Biotechnology 13 (31%)
- Medical Device 13 (31%)
- Therapeutics 8 (19%)
Stage
- Series B 12 (29%)
- Series A 11 (26%)
- Series C 6 (14%)
- Seed 4 (10%)
- Venture - Series Unknown 3 (7%)
Country
- Italy 12 (29%)
- Switzerland 5 (12%)
- United Kingdom 3 (7%)
- Ireland 2 (5%)
- United States 2 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alessio Beverina
Co-Founder & General Partner
|
Co-Founder & General Partner | Total investments: 10 | Find email | |
Fabrizio Landi
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 1 | Find email | |
Barbara Castellano
Partner
|
Partner | Total investments: 7 | Find email | |
Diana Saraceni
General partner
|
General partner | Total investments: 5 | Find email | |
Rob Woodman
Partner
|
Partner | Total investments: 15 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Endovascular Engineering
|
Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis. | $80M / Series C / Apr 07, 2026 | |
DISCO Pharmaceuticals
|
DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells. | $42.3M / Seed / Dec 11, 2025 | |
NanoPhoria
|
NanoPhoria is a biotechnology company focused on the development of innovative cardiovascular treatments. It specializes in a non-viral, nano-in-micro delivery system for biologics, designed to target the heart directly. This preclinical stage company is exploring the potential of inhalable therapies, utilizing tissue-directed delivery methods fortherapeutic peptides and RNAs. NanoPhoria's approach aims to revolutionize the treatment of cardiovascular diseases by offering a versatile, non-viral drug delivery platform, formulated for both inhalation and other administration routes. With a dedicated team, NanoPhoria is committed to advancing cardiovascular health through groundbreaking research and development. | $97.8M / Series A / Oct 06, 2025 | |
Salvia BioElectronics
|
Salvia BioElectronics develops innovative neuromodulation devices aimed at treating migraines. The company focuses on creating a paper-thin implant that delivers gentle electrical pulses to specific nerves, helping to alleviate migraine symptoms. Salvia BioElectronics is dedicated to advancing its technology through ongoing research and developmentefforts. With recent funding, the company works to bring its migraine therapy to market, offering a new approach to pain management for patients. The emphasis is on improving patient outcomes through effective neuromodulation therapy. | $60.1M / Series B / May 27, 2025 | |
DeepUll
|
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $56.9M / Series C / Apr 29, 2025 | |
Relief
|
Relief provides a solution that is uni-sex, easy to use, minimally invasive, fast to insert or remove, and invisible. Their services include urinary incontinence, artificial sphincters, innovative solutions, and medical devices. | $1.1M / Venture - Series Unknown / Mar 05, 2025 | |
Approxima
|
Approxima is an early-stage MedTech startup that is creating a percutaneous tricuspid valve replacement method. The company is demonstrating in vivo safety, efficacy, and feasibility through preclinical feasibility phase trials. | $7.7M / Series A / Feb 20, 2025 | |
|
Endovascular Engineering
|
Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis. | $42M / Series B / Feb 18, 2025 | |
TENSIVE
|
Tensive is a biomedical startup established in 2012 to develop innovative prostheses aiming to offer a natural breast reconstruction or augmentation.Tensive is a biomedical startup established in 2012 to develop innovative prostheses aiming to offer a natural breast reconstruction or augmentation. | $14.6M / Series A / Jan 29, 2025 | |
Lymphatica Medtech
|
Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle. | $19.6M / Series B / Oct 08, 2024 | |
| See all 42 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Panakes Partners invest in?
Panakes Partners invests primarily in Health Care, Medical and Biotechnology startups, most often at Series B and Series A stage. Most of the 42 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Panakes Partners's check size?
Panakes Partners typically joins rounds of $4.5M–$79M at Series A, $10M–$60M at Series B and $18M–$110M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Panakes Partners participates in.
How do I contact Panakes Partners?
Public channels for Panakes Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Panakes Partners?
The team at Panakes Partners includes Alessio Beverina (Co-Founder & General Partner), Fabrizio Landi (Founder and Managing Partner) and Barbara Castellano (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
